Provided by Tiger Trade Technology Pte. Ltd.

Array Digital Infrastructure Inc.

35.59
-1.2600-3.42%
Post-market: 35.590.00000.00%19:30 EDT
Volume:711.93K
Turnover:25.57M
Market Cap:3.07B
PE:5.75
High:36.80
Open:36.40
Low:35.52
Close:36.85
52wk High:60.82
52wk Low:33.71
Shares:86.38M
Float Shares:15.56M
Volume Ratio:2.30
T/O Rate:4.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.19
EPS(LYR):0.5551
ROE:22.68%
ROA:0.02%
PB:2.43
PE(LYR):64.12

Loading ...

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

GlobeNewswire
·
Aug 06

Array Digital Infrastructure Inc Expected to Post Earnings of 62 Cents a Share - Earnings Preview

Reuters
·
Aug 05

A Closer Look at the Latest IPO: Can Zhiyi Bio's Pioneering Live Biotherapeutic Pipeline Unlock Untapped Potential?

Stock News
·
Aug 04

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

GlobeNewswire
·
Aug 04

Earning Preview: Array Digital Infrastructure Inc. Q2 revenue is expected to decrease by 94.24%, and institutional views are cautious

Earnings Agent
·
Aug 01

Array Digital Infrastructure Schedules Quarterly Results Conference Call

Reuters
·
Jul 31

Array Digital Infrastructure Inc Expected to Post Earnings of 62 Cents a Share - Earnings Preview

Reuters
·
Jul 30

Incyte says EC approves Opzelura cream for treatment of AD

TIPRANKS
·
Jul 29

FAA proposes to adopt new AD for Boeing planes, to inspect seat installation

TIPRANKS
·
Jul 28

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

GlobeNewswire
·
Jul 28

T-mobile US Inc. Stock Advances 5.7%, Outperforms Market

Dow Jones
·
Jul 25

T-mobile US Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 21

T-mobile US Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 17

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

GlobeNewswire
·
Jul 15

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

GlobeNewswire
·
Jul 14

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

GlobeNewswire
·
Jul 14

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

GlobeNewswire
·
Jul 13

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

GlobeNewswire
·
Jul 12

RBC Capital Sticks to Its Hold Rating for Array Digital Infrastructure (AD)

TIPRANKS
·
Jul 11

T-mobile US Inc. Stock Climbs 3.4%, Outperforms Peers

Dow Jones
·
Jul 11